Docoh
Loading...
Sign up Log in

BAX Baxter International

Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Company profile

Ticker
BAX
Exchange
NYSE
Website
www.baxter.com/
CEO
Jose Almeida
Employees
Incorporated
Delaware
Location
Illinois
Fiscal year end
Dec 31
Sector
Manufacturing > Surgical and Medical Instrument Manufacturing
Industry (SIC)
Surgical & Medical Instruments & Apparatus
Boston Scientific • Becton, Dickinson And • 3M • Stryker • Teleflex • Resmed • Hill-Rom • Integra Lifesciences • Nuvasive • Haemonetics ...
SEC CIK
0000010456
Corporate docs
IRS number
360781620

BAX stock data

(
)

News

Pro users get this 30m faster
Baxter's AK 98 Hemodialysis Machine Ok'd In US
12 Mar 21
The FDA has approved Baxter International Inc's (NYSE:
Baxter Announces US FDA 510(k) Clearance Of AK 98 Hemodialysis Machine
12 Mar 21
Latest technology offers a compact, portable and easy-to-use system for dialysis providers Includes two-way connectivity to securely transfer prescription and treatment data Can be used alongside Theranova,
Baxter To Offer Fill/Finish Services To Moderna's COVID-19 Vaccine In US
8 Mar 21
A Look Into Baxter's Debt
8 Mar 21
Moderna, Baxter BioPharma Solutions Announce Agreement For Fill/Finish Manufacturing Of Moderna COVID-19 Vaccine In The U.S.
8 Mar 21

Press releases

Pro users get this 30m faster
Baxter to Present at the BofA Securities 2021 Virtual Health Care Conference
7 Apr 21
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021. Jay Saccaro, Baxter's chief financial
Baxter To Host Its Annual Meeting Of Stockholders In Virtual Format
30 Mar 21
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, its Annual
Baxter Launches Initiative to Increase Awareness and Education in Black Communities About Kidney Health and Managing Chronic Kidney Disease
29 Mar 21
During National Kidney Month, Baxter joins forces with not-for-profit organizations The Links and the National Kidney Foundation of Illinois Initiative aims to improve kidney health in the Black community, encourage
Baxter to Host First-Quarter 2021 Financial Results Conference Call for Investors
24 Mar 21
Baxter Announces U.S. FDA 510(k) Clearance of AK 98 Hemodialysis Machine
12 Mar 21

Calendar

11 Feb 21
18 Apr 21
31 Dec 21

Financial summary

Financial statements Chart BAX financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 3.74B 3.74B 3.74B 3.74B 3.74B 3.74B
Cash burn (monthly) 210M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 759.69M n/a n/a n/a n/a n/a
Cash remaining 2.98B n/a n/a n/a n/a n/a
Runway (months of cash) 14.2 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Recent insider trades

BAX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Apr 21 Frye Andrew Common Stock, $1 par value Sell Dispose S No Yes 84.79 10,999 932.61K 9,041
5 Apr 21 Hellman Peter S Common Stock, $1 par value Sell Dispose S No No 84.56 4,990 421.95K 25,399
5 Apr 21 Hellman Peter S Common Stock, $1 par value Option exercise Aquire M No Yes 31.26 4,990 155.99K 30,389
5 Apr 21 Hellman Peter S Stock Option Common Stock, $1 par value Option exercise Dispose M No Yes 31.26 4,990 155.99K 0
5 Apr 21 Stroucken Albert P L Common Stock, $1 par value Sell Dispose S No No 84.56 4,990 421.95K 31,896
5 Apr 21 Stroucken Albert P L Common Stock, $1 par value Option exercise Aquire M No Yes 31.26 4,990 155.99K 36,886
5 Apr 21 Stroucken Albert P L Stock Option Common Stock, $1 par value Option exercise Dispose M No Yes 31.26 4,990 155.99K 0
22 Mar 21 Stevens Brian Common Stock, $1 par value Payment of exercise Dispose F No No 81.24 155 12.59K 18,854
3 Mar 21 Almeida Jose E Stock Option Common Stock, $1 par value Grant Aquire A No No 77.15 348,483 26.89M 348,483
6 Jan 21 Hellman Peter S Stock Option Common Stock, $1 par value Gift Aquire G Yes No 88.74 5,293 469.7K 5,293
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

BAX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

84.6% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 1076 1067 +0.8%
Opened positions 118 79 +49.4%
Closed positions 109 122 -10.7%
Increased positions 322 336 -4.2%
Reduced positions 398 408 -2.5%
13F shares
 Current Prev Q Change
Total value 34.3B 34.04B +0.8%
Total shares 427.39M 423.36M +1.0%
Total puts 1.28M 1.49M -14.3%
Total calls 1.39M 1.47M -5.6%
Total put/call ratio 0.9 1.0 -9.2%
Largest owners
 Shares Value Change
Wellington Management 41.37M $3.32B +43.9%
BLK Blackrock 40.94M $3.28B -8.2%
Vanguard 39.18M $3.14B -0.6%
MS Morgan Stanley 24.07M $1.93B +1.0%
STT State Street 21.05M $1.69B -5.2%
Generation Investment Management 17.42M $1.4B +46.9%
Capital International Investors 12.54M $1.01B +4.9%
Veritas Asset Management 11.11M $891.48M +1.4%
Capital World Investors 9.32M $747.52M +77.6%
AMP Ameriprise Financial 8.5M $682.06M -1.7%
Largest transactions
 Shares Bought/sold Change
Wellington Management 41.37M +12.62M +43.9%
Norges Bank 5.92M +5.92M NEW
Generation Investment Management 17.42M +5.57M +46.9%
JPM JPMorgan Chase & Co. 2.77M -4.36M -61.1%
Capital World Investors 9.32M +4.07M +77.6%
BLK Blackrock 40.94M -3.66M -8.2%
MKFCF Mackenzie Financial 188.18K -3.45M -94.8%
FMR 983.72K -3.11M -76.0%
Mawer Investment Management 921.29K -2.32M -71.6%
D1 Capital Partners 2.05M +2.05M NEW
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
ThermoGenesis • AIM ImmunoTech • Sangamo Therapeutics • United Health Products • Edwards Lifesciences • Curis • Lemaitre Vascular • Nephros • GlycoMimetics • Acelrx Pharmaceuticals
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: acid, admission, Alcoa, Aluminum, amino, appeal, BaxU, BD, Black, BofA, Borzi, Caelyx, CAGR, cancer, cease, chemotherapy, choice, Citigroup, cleaning, content, crucial, cybersecurity, default, Delinquent, Deutsche, divestiture, Doxil, doxorubicin, economy, encompassing, encourage, EPA, escalating, ESRD, faith, feedback, firmly, frequency, gave, GlaxoSmithKline, Goldman, GPA, Grandfathered, Hydro, induce, infection, influence, insolvency, interbank, Johnson, learning, Lennox, LIBOR, lieu, liposomal, logistical, London, lump, Marketplace, mindset, monthly, motivate, movement, multidimensional, nausea, NAV, nonrecurring, OUS, Overnight, petitioning, platform, postponed, preferential, prioritize, prioritized, pronouncement, proper, racial, ran, remote, remotely, resumption, retaliation, retention, revert, revocation, rooted, run, Rupee, sanitation, shelter, shown, SOFR, spread, sum, superior, Supreme, survey, tariff, tasked, telecommunication, Today, transplantation, tuition, underway, unemployment, unintended, unprecedented, virtual, vital, vomiting, widely
Removed: assume, attended, book, bribery, consultation, continuously, cooperating, cover, cyclophosphamide, deconsolidated, deconsolidating, deconsolidation, demanding, derived, desired, ending, FASB, feasibility, Fifty, financially, fiscal, galaxy, implied, imposition, indirectly, integrating, interim, investigative, Irvine, Jayuya, moving, MSA, partial, presidential, prosecution, reallocation, repatriated, resolved, salary, simplify, split, stake, Supplementary, technique, trademark, TSA, Venezuela, Venezuelan, volume, weakening, Western, windfall
From filing 10-K 2020 FY

Financial reports

View all
10-K
2020 FY
Annual report
11 Feb 21
10-Q
2020 Q3
Quarterly report
29 Oct 20
10-Q
2020 Q2
Quarterly report
30 Jul 20
10-Q
2020 Q1
Quarterly report
30 Apr 20
10-K
2019 FY
Annual report
17 Mar 20
10-Q
2019 Q3
Quarterly report
17 Mar 20
NT 10-K
Notice of late annual filing
3 Mar 20
NT 10-Q
Notice of late quarterly filing
13 Nov 19
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
7 May 19

Current reports

View all
8-K
Baxter Appoints DR. David Wilkes to Its Board and Albert Stroucken As Lead Independent Director
16 Feb 21
8-K
Baxter Reports Fourth-quarter and Full-year 2020 Results
4 Feb 21
8-K
Results of Operations and Financial Condition
11 Jan 21
8-K
Departure of Directors or Certain Officers
20 Nov 20
8-K
Entry into a Material Definitive Agreement
6 Nov 20
8-K
Baxter Announces Proposed $650 Million Senior Notes Offering
29 Oct 20
8-K
Baxter Reports Third-quarter 2020 Results
29 Oct 20
8-K
Regulation FD Disclosure
8 Oct 20
8-K
Regulation FD Disclosure
28 Sep 20
8-K
Departure of Directors or Certain Officers
25 Sep 20

Registration and prospectus

View all
424B3
Prospectus supplement
14 Apr 21
S-4
Registration of securities issued in business combination transactions
7 Apr 21
15-12B
Securities registration termination
15 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 21
8-A12B
Registration of securities on exchange
15 May 19
424B2
Prospectus for primary offering
14 May 19
FWP
Free writing prospectus
10 May 19
424B5
Prospectus supplement for primary offering
10 May 19

Proxies

View all
PX14A6G
Letter to shareholders
31 Mar 21
DEFA14A
Additional proxy soliciting materials
22 Mar 21
DEF 14A
Definitive proxy
22 Mar 21
DEFA14A
Additional proxy soliciting materials
21 Apr 20
DEFA14A
Additional proxy soliciting materials
31 Mar 20
DEFA14A
Additional proxy soliciting materials
17 Mar 20
DEF 14A
Definitive proxy
17 Mar 20
DEFA14A
Additional proxy soliciting materials
26 Mar 19
DEF 14A
Definitive proxy
26 Mar 19
DEF 14A
Definitive proxy
22 Mar 18

Other

View all
EFFECT
Notice of effectiveness
15 Apr 21
SD
Conflict minerals disclosure
1 Jun 20
SD
Conflict minerals disclosure
24 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
30 May 17
CERTNYS
Certification of approval for NYSE listing
29 May 17
UPLOAD
Letter from SEC
9 May 17
CORRESP
Correspondence with SEC
27 Apr 17
CORRESP
Correspondence with SEC
13 Apr 17
UPLOAD
Letter from SEC
30 Mar 17

Ownership

View all
4
BAXTER INTERNATIONAL / Andrew Frye ownership change
14 Apr 21
SC 13G/A
BAXTER INTERNATIONAL / WELLINGTON MANAGEMENT ownership change
12 Apr 21
4
BAXTER INTERNATIONAL / ALBERT P L STROUCKEN ownership change
7 Apr 21
4
BAXTER INTERNATIONAL / PETER S HELLMAN ownership change
7 Apr 21
4
BAXTER INTERNATIONAL / Brian Stevens ownership change
24 Mar 21
4
BAXTER INTERNATIONAL / Giuseppe Accogli ownership change
5 Mar 21
4
BAXTER INTERNATIONAL / Brian Stevens ownership change
5 Mar 21
4
BAXTER INTERNATIONAL / JAMES SACCARO ownership change
5 Mar 21
4
BAXTER INTERNATIONAL / Jeanne K Mason ownership change
5 Mar 21
4
BAXTER INTERNATIONAL / Sean Martin ownership change
5 Mar 21

Patents

View all
GRANT
Utility
Control of a water device via a dialysis machine user interface
13 Apr 21
A home medical device system includes a home therapy machine for performing a home therapy on a patient; a user interface operably connected to the home therapy machine, the user interface receiving operator inputs; a water treatment device in fluid communication with the home therapy machine; and a data connection between the home therapy machine and the water treatment device, wherein the home therapy machine transmits data via the connection to the water treatment device for control of the water treatment device, the data provided based on at least one of the operator inputs received via the user interface.
GRANT
Utility
Irradiated membrane for cell expansion
13 Apr 21
A membrane for cultivating adherent or suspension cells, in particular adherent cells.
GRANT
Utility
Bar-type parameter adjustment elements
13 Apr 21
Graphical user interfaces for use with extracorporeal blood treatment systems may include one or more bar-type parameter adjustment elements.
APP
Utility
Fluid Temperature Control Device for an Extracorporeal Blood Treatment Apparatus and Extracorporeal Blood Treatment Apparatus
8 Apr 21
A fluid temperature control device for an extracorporeal blood treatment apparatus, comprises: a casing (26) delimiting a heating/cooling seat (20) configured to accommodate a fluid warming bag (17) connected or connectable to an extracorporeal blood treatment apparatus (1); heating elements (29, 30) operatively active in the heating seat (20) to heat the fluid warming bag (17); at least a presence detector (32, 33) operatively active in the heating seat (20) to detect the presence of the fluid warming bag (17).
APP
Utility
a Connector Arrangement, a System for Extracorporeal Blood Treatment and a Method for Priming a Fluid Chamber of a Blood Treatment Unit
8 Apr 21
A connector arrangement (10) for connecting to a fluid chamber (6) of a blood treatment unit (4) for extracorporeal blood treatments.

Transcripts

View all
2020 Q4
Earnings call transcript
4 Feb 21
2020 Q3
Earnings call transcript
29 Oct 20
2020 Q2
Earnings call transcript
30 Jul 20
2020 Q1
Earnings call transcript
30 Apr 20
2019 Q4
Earnings call transcript
17 Mar 20
2019 Q3
Earnings call transcript
24 Oct 19
2019 Q2
Earnings call transcript
25 Jul 19
2019 Q1
Earnings call transcript
25 Apr 19
2018 Q4
Earnings call transcript
31 Jan 19
2018 Q3
Earnings call transcript
31 Oct 18

Reddit threads

View all